Our Stem Cell Therapy
Regenerative Medical Solutions has developed stem cell technology to revolutionize the treatment of diabetes and enable future research and drug discovery.
Cutting-Edge Stem Cell Technology for Creating Islet-Like Cluster Cells
RegenMed Solutions has developed a novel and proprietary ILC cell technology to transform stem cells into insulin-producing cells.
Typically, in healthy humans, insulin is produced within pancreatic islets, by beta cells (β-cells). Our stem cell technology has enabled us to develop pancreatic islet like cluster (ILC) cells that are morphologically and functionally similar to β islet cells isolated from the human body. They contain glucagon-producing alpha cells, somatostatin-producing delta cells and insulin-producing β islet cells.
RMS is utilizing and building upon patented technology developed at RMS and the University of Wisconsin–Madison under world-renowned stem cell scientist and pancreatic transplant surgeon, Dr. Jon Odorico, and RMS’ dedicated team of scientists. Dr. Odorico has been working in the field of stem cells, diabetes and regenerative medicine for over 20 years, and has previously collaborated with Dr. James Thomson, a pioneer in stem cell research.
iPSC Therapy: Ethical Stem Cell Technology
RMS’s stem cell therapy is an ethical choice, as it uses induced pluripotent stem cells (iPSCs) instead of embryonic stem cells.
Embryonic stem cells come from embryos, whereas induced pluripotent stem cells come from adults. However, unlike typical adult cells, iPSCs have been reprogrammed so they can mimic any cell in the body, just like embryonic stem cells can.
Our stem cell therapy for diabetes is therefore a type of iPSC therapy. This choice of stem cell technology is ideal, as it avoids the ethical concerns of embryo use, and enables us to transform the patient’s own stem cells into insulin-producing cells, so there’s no chance of rejection.
Stem Cell Therapy as a Candidate for Diabetes Treatment
RMS’s innovative diabetes cellular therapeutic, currently in pre-clinical development, leverages stem cell technology to create Islet-Like Clusters (ILCs) aimed at treating both Type 1 and Type 2 diabetes. By utilizing both autologous and allogeneic approaches, RMS is developing therapies where patient-derived or donor-derived iPSCs are differentiated into ILCs, which can be transplanted to restore insulin production and regulate blood glucose levels. This promising therapeutic candidate has the potential to offer a functional cure for diabetes, addressing the underlying cause of insulin deficiency, and is progressing towards clinical trials to assess its safety and efficacy.
Research Applications for Our Stem Cell Therapy
The primary goal of our iPSC therapy is to cure type 1 and type 2 diabetes. However, our work can also help other pharmaceutical and biotech companies continue their research.
ILC Cell Kit: RMS has developed an ILC Cell Kit which contains specially formulated cryopreserved single cell ILC’s that can be used for diabetes research, drug discovery, and toxicity testing. These ILCs closely resemble human cadaveric islet’s morphologically, express similar key pancreatic markers (NKX6.1 and PDX1), and have functional insulin production. RMS ILCs can offer a reliable and scalable option for researchers and pharmaceutical developers to advance diabetes treatments and better understand cellular responses in pre-clinical trials.
ProgenMix™ Media Formulation: This pancreatic differentiation protocol is designed for robust generation of PDX1+ pancreatic progenitor cells and endocrine cell types. ProgenMix™ allows researchers to develop the cells themselves, rather than purchasing them in the ILC Cell Kit.
Patented Breakthroughs in Stem Cell Technology
RegenMed Solutions has built a substantial IP and know-how (trade secret) portfolio over the years, in additional to exclusive and non-exclusive licensing of IP from academic institutions.
- Issued Patent (8,685,730): Methods and Devices for Differentiating Pluripotent Stem Cells into Cells of the Pancreatic Lineage.
- Issued Patent (9,540,613 B2), RMS was a co-inventor with University of Wisconsin: Methods for Producing Insulin-Secreting Beta Cells from Human Pluripotent Stem Cells.
- Issued Patent (9,828,634): Markers for Differentiation of Stem Cells into Differentiated Cell Populations.
- Issued Patent (9,765,302): Compositions and Methods for Differentiating Stem Cells into Cell Populations Comprising Beta-Like Cells.
- Non-exclusive license from Academia Japan to practice iPSC methods for both research tools and therapy.
Why Choose RMS?
Regenerative Medical Solutions offers a unique opportunity to support the development of a cutting-edge cure for diabetes using iPSC therapy. Backed by ethical stem cell research and technology, we are leading the way to a diabetes cure that does not use embryonic stem cells, works for all blood types, and eliminates the need for anti-rejection drugs. Our prospective diabetes cure uses regenerative cellular therapy to create a scalable solution, that is designed to affordably replace insulin for millions of individuals suffering with diabetes. Our stem cell therapy is intended to be the breakthrough the diabetes industry needs.
Contact and Collaboration
We are currently progressing through clinical trials to bring our stem cell therapy for diabetes to market. This provides a unique opportunity for venture capitalists, pharmaceutical companies, and researchers to collaborate with our team and invest in our work.
Contact us or request investor materials to learn more.
Stem Cell Therapy FAQs
Stem cells offer great opportunity in medicine, as they are not yet specialized. This means that they can be differentiated to function as other cells in the body. Stem cell therapy involves utilizing stem cells for medical purposes. For RMS, this means turning stem cells into insulin-producing cells, to treat diabetes.
No. Some stem cell research uses human embryos, but RegenMed Solutions does not use embryonic stem cells in its work. We use induced pluripotent stem cells, which come from adults. In fact, we intend to use patients’ own cells for this process, to eliminate the chance of rejection and enable patients living with diabetes to produce their own insulin again.
iPSC therapy is stem cell therapy using induced pluripotent stem cells. These are adult stem cells that have been reprogrammed so that they can be differentiated into any other type of cell.
